@blue30 not sure if much will happen if at all until the AGM, even then we may not get much. If you look at the graphs in the annual report it shows that the lead BARD1 PRODUCT for detecting Ovarian cancer in high risk individuals is part way through the assay development phase and yet to be clinically validated with the only revenue raiser being the hTERT screening kit for bladder cancer...we n will have to wait until another revenue raiser comes on board, and then I suspect the rest with come in a hurry
Ann: Appendix 4E and Annual Report to Shareholders, page-9
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
56.0¢ |
Change
-0.010(1.75%) |
Mkt cap ! $59.09M | |||
| Open | High | Low | Value | Volume |
| 57.0¢ | 57.0¢ | 54.0¢ | $96.73K | 176.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 12 | 55.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 56.0¢ | 7999 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |